On the basis of the structure of the non-peptide receptor antagonist irbesartan, a new series of AT1 ligands was designed. In these compounds the central imidazolone nucleus of irbesartan was replaced by a pyrazolidine-3, 5-dione structure. The key intermediate N- alkylpyrazolidine-3, 5-diones were synthesized according to a new and general method. The most active compounds possess a spirocyclopentane ring at position 4, a linear butyl ...
